个人简历

学科方向\t 药物标靶的疾病分子机制研究
叶丽虹，博士生导师，南开大学特聘教授。任中国抗癌协会肿瘤标志物专业委员会常委、肿瘤转移专业委员会委员、中国生物化学与分子生物技术专业委员会委员、中国生物化学与分子生物学学报编委、天津市侨联常委、南开大学工会和教代会委员及校工会女工委员会委员。叶丽虹于1983年获得中国医科大学医疗系本科医学学士学位，同年到辽宁医学院药理教研室任教。1989年获延边大学医学部药理学硕士学位；同年到大连医科大学任药学系讲师。1992年到日本文部省奖学金赴日本群马大学医学部留学，1997年获医学博士学位（M.D., Ph.D.）。在日本学术振兴会（JSPS）奖学金资助下完成了两年博士后训练，之后就职于日本理化学研究所任研究员。2000年末以“引进人才”到南开大学生命科学学院任教授、博士生导师和蛋白质生化研究室学术带头人。2015年1月加入药物化学生物学国家重点实验室。
叶丽虹教授实验室主要从事肿瘤发生发展分子机制和抗肿瘤药物筛选等研究。在国际上首次报道了新的癌基因HBXIP可作为众多关键癌基因的转录辅激活因子在肿瘤的生长、转移、血管生成、免疫逃逸和糖脂代谢等过程中的重要作用及其分子调控机制。迄今共发表学术论文182篇，其中论著132篇（SCI 论著96篇）。2010年以来作为通讯作者在国际期刊上发表SCI 论著61 篇，其中发表在著名的国际期刊有1篇《Hepatology》、 3 篇《Cancer Research》、 1篇《Cell Research》、3 篇《Oncogene》、5篇《J.B.C》和4 篇《Carcinogenesis》等。回国后主持基金项目14项（973前期课题1项，国家自然科学基金8项，教育部和天津市基金5项），作为骨干参加973两项。在美国Nova科学出版社出版专著2部，参编学术专著3部；申请国家发明专利18项，获得国家发明专利6项。曾荣获全国“新世纪巾帼发明家”优秀奖、天津市巾帼发明家创新奖、天津市知识产权系统“十大女杰”、天津市2007年度专利优秀奖等称号。

研究领域

乳腺癌信号通路分子机制和药物作用靶点的研究
新的重要癌蛋白HBXIP致癌分子机制的研究""

近期论文

1. Liu B, Wang T, Wang H, Zhang L, Xu F, Fang R, Li L, Cai X, Wu Y, Zhang WY*, Ye LH*. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. J Hematol Oncol. 2018 Feb 23;11(1):26. 2. Wang T, Liu B, Guan Y, Gong M, Zhang WY, Pan J, Liu Y, Liang R, Yuan Y*, Ye L*. Melatonin inhibits the proliferation of breast cancer cells induced by bisphenol A via targeting estrogen receptor-related pathways. Thorac Cancer. 2018 Mar;9(3):368-375. 3.Li H, Wang Z, Li Y, Fang R, Wang H, Shi H, Zhang X, Zhang W*, Ye L*. Hepatitis B X-interacting protein promotes the formation of the insulin gene-transcribing protein complex Pdx-1/NeuroD1 in animal pancreatic β cells. J Biol Chem. 2018 Feb 9;293(6):2053-2065. 4. Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W*, Ye L*. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2017 Nov 22;415:11-198. 5. Feng GX, Li J, Yang Z, Zhang SQ, Liu YX, Zhang WY*, Ye LH*, Zhang XD*. Hepatitis B virus X protein promotes the development of liver fibrosis and hepatoma through downregulation of miR-30e targeting P4HA2 mRNA. Oncogene. 2017 Dec 14;36(50):6895-6905. 6. Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, Sun M, Zhao M, Chen F, Zhang W, Ye L*, Zhang X*. HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis. Hepatology. 2017 Nov;66(5):1413-1429. 7. Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, Zhang W, Ye L*, Zhang X*. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem. 2017 Sep 15;292(37):15395-15407. 8. Wang Y, Chen F, Yang Z, Zhao M, Zhang S, Gao Y, Feng J, Yang G, Zhang W, Ye L*, Zhang X*. The Fragment HMGA2-sh-3p20 from HMGA2 mRNA 3'UTR Promotes the Growth of Hepatoma Cells by Upregulating HMGA2. Sci Rep. 2017 May 18;7(1):2070. 9. Zhang SQ, Yang Z, Cai XL, Zhao M, Sun MM, Li J, Feng GX, Feng JY, Ye LH, Niu JQ*, Zhang XD*. miR-511 promotes the proliferation of human hepatoma cells by targeting the 3'UTR of B cell translocation gene 1 (BTG1) mRNA. Acta Pharmacol Sin. 2017 Aug;38(8):1161-1170. 10. Yang G, Wang Y, Feng J, Liu Y, Wang T, Zhao M, Ye L, Zhang X*. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling. Biochem Biophys Res Commun. 2017 May 6;486(3):827-832. 11. Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L*, Zhang X*. Anti-HBV Drugs Suppress the Growth of HBV-related Hepatoma Cells via Down-regulation of Hepatitis B Virus X Protein. Cancer Lett. 2017 Apr 28;392:94-104. 12. Cai X, Cao C, Li J, Chen F, Zhang S, Liu B, Zhang W*, Zhang X*, Ye L*. Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1. Oncotarget. 2017 Apr 6;8(35):58338-58352. 13. Yang Z, Li J, Feng G, Gao S, Wang Y, Zhang S, Liu Y, Ye L, Li Y*, Zhang X*. MicroRNA-145 Modulates N6 methyladenosine Levels by Targeting the 3' Untranslated mRNA Region of the N6-methyladenosine binding YTH Domain Family 2 Protein. J Biol Chem. 2017 Mar 3;292(9):3614-3623. 14. Wang Y, Cai X, Zhang S, Cui M, Liu F, Sun B, Zhang W, Zhang X, Ye L*. HBXIP up-regulates ACSL1 through activating transcriptional factor Sp1 in breast cancer. Biochem Biophys Res Commun. 2017 Mar 11;484(3):565-571. 15. Wang Y, Fang R, Cui M, Zhang W, Bai X, Wang H, Liu B, Zhang X*, Ye L*. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Cancer Lett. 2017 Jan 28;385:234-242. 16. Wang Y, Chen F, Zhao M, Yang Z, Zhang S, Ye L, Gao H*, Zhang X*. MiR-107 suppresses proliferation of hepatoma cells through targeting HMGA2 mRNA 3'UTR. Biochem Biophys Res Commun. 2016 Nov 18;480(3):455-460. 17. Shi H, Fang R, Li Y, Li L, Zhang W, Wang H, Chen F, Zhang S, Zhang X*, Ye L*. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells. Cancer Lett. 2016 Sep 5;382(2):147-156. 18. Zhao Y, Li H, Zhang Y, Li L, Fang R, Li Y, Liu Q, Zhang W, Qiu L, Liu F, Zhang X*, Ye L*. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activatingthe LXRs/SREBP-1c/FAS Signaling Cascade. Cancer Res.2016 Aug 15;76(16):4696-707 19. Feng G, Li J, Zheng M, Yang Z, Liu Y, Zhang S, Ye L, Zhang W*, Zhang X*. Hepatitis B virus X protein up-regulates C4b-binding protein αthrough activating transcription factor Sp1in protection of hepatoma cells from complement attack. Oncotarget. 2016 May 10;7(19):28013-26. 20. Feng G, Shi H, Li J, Yang Z, Fang R, Ye L, Zhang W*, Zhang X*. MiR-30e suppresses proliferation of hepatoma cells via targeting prolyl 4-hydroxylase subunit alpha-1 (P4HA1) mRNA. Biochem Biophys Res Commun. 2016 Apr 8;472(3):516-22.